Atea/ NO0004822503 /
| 2024-04-19 4:19:33 PM | Chg. - | Volume | Bid4:30:00 PM | Ask4:30:00 PM | High | Low |
|---|---|---|---|---|---|---|
| 131.00NOK | - | 1,172 Turnover: 153,693.60 |
-Bid Size: - | -Ask Size: - | 131.40 | 131.00 |
GlobeNewswire
04-29
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID...
GlobeNewswire
03-27
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral ...
GlobeNewswire
02-28
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Busine...
GlobeNewswire
02-21
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on ...
GlobeNewswire
01-08
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) ...
GlobeNewswire
01-03
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
2023-11-13
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatmen...
GlobeNewswire
2023-11-08
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
2023-11-08
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
GlobeNewswire
2023-11-02
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Vir...
GlobeNewswire
2023-11-01
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 202...
GlobeNewswire
2023-09-06
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
GlobeNewswire
2022-03-28
Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxico...
GlobeNewswire
2022-02-28
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Busine...
GlobeNewswire
2022-02-22
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on ...
GlobeNewswire
2022-02-10
Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Precli...
GlobeNewswire
2022-02-09
Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference
GlobeNewswire
2022-02-02
Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvir’s (AT-527) Novel Mechani...
GlobeNewswire
2022-02-02
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atea Pharmaceuti...
GlobeNewswire
2022-01-23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atea Pharmaceuti...
GlobeNewswire
2022-01-13
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atea Pharmaceuti...
GlobeNewswire
2022-01-03
Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
GlobeNewswire
2021-12-14
Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19
